(Q34768542)

4 August 2017

title

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers (English)

1 reference

4 August 2017

1 reference

2

Deanna Teoh

1 reference

4 August 2017

John K Chan

1

1 reference

4 August 2017

Jessica M Hu

3

1 reference

4 August 2017

Jacob Y Shin

4

1 reference

4 August 2017

Kathryn Osann

5

1 reference

4 August 2017

Daniel S Kapp

6

1 reference

4 August 2017

language of work or name

English

0 references

publication date

18 April 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

109

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

370-376

1 reference

4 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Clear cell carcinoma of the ovary: a study of 59 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Survival probability in ovarian clear cell adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Clinicopathologic analysis of early-stage sporadic ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

PIEPOC: a new prognostic index for advanced epithelial ovarian cancer--Japan Multinational Trial Organization OC01-01.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Ovarian clear cell adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Studying radiation therapy using SEER-Medicare-linked data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Comparative study of ovarian cancer histopathology by registry pathologists and referral pathologists: a study by the Gilda Radner Familial Ovarian Cancer Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.006

10.1016/J.YGYNO.2008.02.006

7 January 2021

Identifiers

DOI

1 reference

4 August 2017

1 reference